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Asthma is an important public health problem that affects
people of all ages and causes significant health resource uti-
lization.1 Its prevalence varies widely in different regions,
and a “precise and universally accepted definition of asthma”
is still lacking.2 In fact, estimates obtained in epidemiological
studies, on both adults3 and children,4 are highly dependent
on the set of questions used for the operational definition of
asthma.
In a clinical context, the initial diagnosis of asthma is based on
identifying a pattern of respiratory symptoms, supported by
pulmonary function tests, including the study of airflow
obstruction reversibility and/or bronchial hyperresponsiveness.1
However, because these procedures are seldom feasible in
population-based studies, efforts have been made to find accurate
definitions of asthma on the basis of questionnaires. In 2014, we
proposed a set of questions to be reported in population-based
studies on asthma prevalence on the basis of a literature review
of the different asthma definitions used in epidemiological
studies.3
Several prediction models have been previously developed to
identify children with asthma-like symptoms. A systematic re-
view5 on prediction models for children reported extensive
variability both on predictors and on outcome definitions and
that none had the ability to rule in and rule out asthma simul-
taneously. In adults, Pekkanen et al6 developed a continuous
asthma score to define asthma on the basis of the European
Community Respiratory Health Survey (ECRHS) questionnaire
and used bronchial hyperreactivity as the comparator. This score
showed good predictive capability in a prospective study when
compared with self-reported use of asthma medication and
asthma attacks and with bronchial hyperreactivity test at the end
of follow-up.7 However, its validity was not supported by the
results in another population setting.8 The ECRHS score wasalso compared with the self-reported previous diagnosis of
asthma8 but not against in-person physician diagnosis confirmed
after clinical examination. This study argued on the use of a
continuous score over a dichotomous definition of asthma, but in
fact, the choice of a cutoff depends mainly on the aims of the
classification. Self-reported questionnaires are tools used to
identify asthma in prevalence studies assessing participants only
once (eg, the Global Allergy and Asthma Network of Excellence
[GA2LEN] survey9) and are also used as initial screening ques-
tionnaires, being a feasible and effective way for preselecting
patients for additional diagnostic workup, including pulmonary
function tests (eg, the ECRHS10). Screening questionnaires are
often used in epidemiological studies on chronic obstructive
pulmonary disease (COPD),11,12 and their development was
encouraged by the World Health Organization.13
To our knowledge, the existing score system for the identifi-
cation of asthma in adults, based on self-administered ques-
tionnaires, has not been validated against actual diagnostic
workup by a trained physician. Furthermore, it is lacking a
screening questionnaire to rule in and rule out asthma, enabling
its use both in population-based studies and in screening/triage
clinical settings. We aimed to (1) develop and validate multi-
variable scores for adult asthma identification in epidemiological
studies on the basis of answers to questions commonly used in
these studies and (2) to explore the best cutoff to rule in asthma
(preferable in prevalence studies) and to rule out asthma (pref-
erable for screening/triage).METHODS
Source of data
We used data from the Control and Burden of Asthma and
Rhinitis (ICAR) study (PTDC/SAU-SAP/119192/2010), a nation-
wide population-based observational cross-sectional study conducted
in Portugal (ClinicalTrials.gov: NCT01771120). The study was
approved by a hospital ethics committee (Comissão de Ética do
Hospital São João EPE, on October 17, 2011) and by the national
data protection committee (no. 12372/2011). All participants signed
the consent form.
Methods regarding sample size calculations, participants, and data
collection in the ICAR study are described in the “Methods” section
in this article’s Online Repository at www.jaci-inpractice.org. Data
collection included lung function and exhaled nitric oxide, skin prick
tests, a structured clinical assessment, and standardized question-
naires. The structured clinical assessment was performed by a trained
physician and included physical examination, use of health resources
and medications because of asthma/rhinitis, and detailed personal
and family medical history. In the ICAR study, self-administered
questionnaires assessed disease symptoms and control, including
the Portuguese version of the GA2LEN survey questionnaire14
among other questionnaires.
Participants
We included participants from the general population aged 18
years and older from the ICAR study (n ¼ 728). Considering an
asthma prevalence of 23% (in the study sample), a specificity of
90%, and a maximum marginal error of estimate not exceeding 3%
with a 95% CI, the required sample size was 498 participants.15
Approximately 80% (n ¼ 560) of the participants were randomly
selected into a derivation cohort and 20% (n ¼ 151) into a vali-
dation cohort.
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Adults
n=728
Children n=130x
Missing data in any 
predictor n=17x
Included
n=711
Asthma
n=29
No asthma
n=122
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FIGURE 1. Participants’ flowchart.Outcome and predictors
Asthma diagnosis (criterion standard) was defined by a physician
on the basis of a structured clinical assessment of symptoms and
detailed medical history, and supported by objective measurements
(see the “Methods” section in this article’s Online Repository), ac-
cording to guidelines. The physician had no previous access to the
results of the self-administered questionnaires.
The predictors were asthma-related questions from the self-
administered questionnaires. Sixteen questions were selected as
initial predictors, namely, (1) questions previously suggested in a
literature review2 and (2) questions on asthma from the GA2LEN
questionnaire (see Table E1 in this article’s Online Repository at
www.jaci-inpractice.org). On the basis of these predictors, 2 separate
scores were built: the Adult Asthma Epidemiological Score (A2
score), based on the literature, and the GA2LEN Asthma Epide-
miological Score (GA2LEN score), based on the GA2LEN
questionnaire.
Subjects with missing data in any of the predictors were excluded
from the analysis (n ¼ 17 [2.3%]).
Statistical analysis methods
Categorical variables are presented as absolute frequencies and
proportions. Comparisons of proportions and associations were
tested. A P value of less than .05 was considered as statistically
significant. Statistical analysis was performed using IBM SPSS Sta-
tistics, version 24.0 (IBM Corp, Armonk, NY).
An exploratory factor analysis was performed to construct a score
reducing the number of predictors while retaining, as much as
possible, the information contained in the initial combination of
predictors, identifying the possible statistical redundancy of the
predictors.16 A factor analysis was run for the initial predictors (see
Table E1 in this article’s Online Repository). Principal-component
analysis and oblimin rotation were used. Predictors with more
than 95% responses in a single category were excluded. An item was
considered redundant and was excluded if any 1 of the following
occurred: highly intercorrelated (>0.900), considerable cross-
loading (>0.300 in more than 1 factor), low item-total correlation
(<0.400), or increased Cronbach a if the predictor was deleted.
Discriminative/predictive power of the scores was evaluated by
receiver-operating characteristic (ROC) curve analysis. Internal
consistency was assessed by Cronbach a. The diagnostic accuracy
measures used were sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and accuracy.
The scores’ performance was tested in the derivation and vali-
dation cohorts and compared with the ECRHS asthma score. The
cutoff to rule in asthma was defined as the minimum number of
positive answers to obtain a PPV of 85% or more simultaneously in
both cohorts. The cutoff to rule out asthma was defined as the
maximum number of positive answers to obtain an NPV of 95% or
more simultaneously in both cohorts.
For each of the 2 scores, 2 scoring methods were tested: the
weighted sum, obtained by multivariable logistic regression of the
included predictors, and the direct sum of the included predictors.
The scores obtained by both the scoring methods were compared by
the Spearman correlation factor. The values for the area under the
ROC curve (AUC) for the scores obtained by both the methods
were also compared.
RESULTS
This study included 711 participants (see Figure 1), with a
median age (percentile 25 to percentile 75) of 42 (32-55) years,and 447 (63%) were females. The number of participants with
asthma was 162 (23%). No statistically significant differences
were observed between the derivation and the validation cohorts
regarding sex, age, geographic region of residence, and presence
of asthma (P > .1). Specifically, no differences between the co-
horts were observed in the proportion of participants with
asthma (23.8% vs 19.2%; P ¼ .24).
In the derivation cohort, having asthma was highly associated
with all the initial predictors but not with the demographic
variables (Table I). In general, the ability to identify patients with
asthma using any asthma predictor alone was low (PPV < 70%;
see Table E2 in this article’s Online Repository at www.jaci-
inpractice.org).
Scores specifications and performance
On the basis of the initial set of questions (see Table E1 in this
article’s Online Repository), 2 scores were developed to identify
the presence of asthma (Table II). The A2 score and the
GA2LEN score derivations were obtained by exploratory factor
analysis (see the “Exploratory factor analysis” section in this ar-
ticle’s Online Repository at www.jaci-inpractice.org). The final
A2 score included 8 predictors in 2 factors with eigenvalues of
3.997 (predictors 2-5 and 10; Table II) and 3.535 (predictors 6-
8). The final GA2LEN score included 6 predictors in 2 factors
with eigenvalues of 2.954 (predictors 6-8; Table II) and 2.860
(predictors 1, 4, and 5).
The discriminative properties of the developed scores were
similar, with an AUC of about 90% (Figure 2). The A2 score
had higher Cronbach a than the GA2LEN score (0.887 vs
0.852, respectively; Figure 2).
The scores obtained by the weighted sum (Table II) were
highly correlated with those obtained by the direct sum
(Spearman correlation coefficient >0.98; P < .001). As so, the
final result was the direct sum of the positive answers to the
questions selected for each score, ranging from 0 to 8 for the A2
score and from 0 to 6 for the GA2LEN score.
Diagnostic accuracy measures were assessed for both scores
and cohorts (Table III; see also Table E3 in this article’s Online
Repository at www.jaci-inpractice.org). As expected, the
TABLE I. Characterization of the cohorts
Characteristic
Derivation cohort Validation cohort
Total
(n [ 560)
Asthma presence
P value
Total
(n [ 151)
Asthma presence
P value
No
(427 [76.3%])
Yes
(133 [23.8%])
No
(122 [80.8%])
Yes
(29 [19.2%])
Demographic characteristics
Age (y), median (P25-P75) 41.5 (32-55) 43 (32-56) 37 (31-55) .119* 42 (33-52) 43 (32-54) 40 (33-48) .501*
Sex, n (%) .302† .903z
Female 360 (64.6) 279 (65.8) 81 (60.9) 87 (57.6) 70 (57.4) 17 (58.6)
Male 197 (35.4) 145 (34.2) 52 (39.1) 64 (42.4) 52 (42.6) 12 (41.4)
Region, n (%) .561x .701x
North 285 (50.9) 216 (50.6) 69 (51.9) 80 (53.0) 66 (54.1) 14 (48.3)
Center 35 (6.3) 27 (6.3) 8 (6.0) 11 (7.3) 10 (8.2) 1 (3.4)
Lisbon 183 (32.7) 139 (32.6) 44 (33.1) 36 (23.8) 27 (22.1) 9 (31.0)
Alentejo 26 (4.6) 18 (4.2) 8 (6.0) 10 (6.6) 6 (4.9) 4 (13.8)
Algarve 31 (5.5) 27 (6.3) 4 (3.0) 14 (9.3) 13 (10.7) 1 (3.4)
Predictors, n (%)
1. Have you ever had asthma?jj{ 138 (24.6) 36 (8.4) 102 (76.7) <.001† 30 (19.9) 10 (8.2) 20 (69.0) <.001†
2. Did a physician confirm you had asthma?jj 132 (23.6) 30 (7.0) 102 (76.7) <.001† 29 (19.2) 10 (8.2) 19 (65.5) <.001†
3. Do you still have asthma (previously diagnosed by a physician)?jj 104 (18.6) 14 (3.3) 90 (67.7) <.001† 24 (15.9) 6 (4.9) 18 (62.1) <.001z
4. Have you ever been hospitalized because of asthma?{ 40 (7.1) 10 (2.3) 30 (22.6) <.001† 8 (5.3) 2 (1.6) 6 (20.7) .001z
5. Have you had any asthma attack in the last 12 mo?jj{ 51 (9.1) 7 (1.6) 44 (33.1) <.001† 7 (4.6) 1 (0.8) 6 (20.7) <.001z
6. Are you currently taking any medicines including inhalers, aerosols, or tablets for
asthma?jj{
66 (11.8) 5 (1.2) 61 (45.9) <.001† 11 (7.3) 1 (0.8) 10 (34.5) <.001z
7. Have you ever had wheezing or whistling in the chest at any time in the last 12 mo?jj{ 178 (31.8) 85 (19.9) 93 (69.9) <.001† 38 (25.2) 17 (13.9) 21 (72.4) <.001†
8. Have you had this wheezing or whistling when you did not have a cold?jj{ 104 (18.6) 41 (9.6) 63 (47.4) <.001† 18 (11.9) 4 (3.3) 14 (48.3) <.001z
9. Have you been at all breathless when the wheezing noise was present?jj{ 118 (21.1) 41 (9.6) 77 (57.9) <.001† 24 (15.9) 7 (5.7) 17 (58.6) <.001z
10. Have you had an attack of shortness of breath after exercise in the last 12 mo?jj 45 (8.0) 16 (3.7) 29 (21.8) <.001† 9 (6.0) 1 (0.8) 8 (27.6) <.001z
11. Have you had an attack of shortness of breath that came on during the day when you
were at rest at any time in the last 12 mo?jj
78 (13.9) 26 (6.1) 52 (39.1) <.001† 13 (8.6) 2 (1.6) 11 (37.9) <.001z
12. Have you woken up with the feeling of tightness in your chest at any time in the last 12
mo?jj{
98 (17.5) 59 (13.8) 39 (29.3) <.001† 25 (16.6) 15 (12.3) 10 (34.5) .010z
13. Have you been woken up by an attack of shortness of breath at any time in the last 12
mo?jj{
57 (10.2) 23 (5.4) 34 (25.6) <.001† 14 (9.3) 8 (6.6) 6 (20.7) .029z
14. Have you been woken up by an attack of coughing at any time in the last 12 mo?jj{ 226 (40.4) 156 (36.5) 70 (52.6) .001† 54 (35.8) 37 (30.3) 17 (58.6) .004†
15. In the last 12 mo, have you had a dry cough during the night, apart from a cough
associated with a cold or a chest infection?jj
222 (39.6) 144 (33.7) 78 (58.6) <.001† 59 (39.1) 40 (32.8) 19 (65.5) .001†
16. Did you have phlegm when coughing for at least 3 mo in the last year?{ 19 (3.4) 8 (1.9) 11 (8.3) .001† 4 (2.6) 2 (1.6) 2 (6.9) .167z
P25-P75, percentile 25 to percentile 75.
*Mann-Whitney U test.
†Chi-square test.
zThe Fisher exact test.
xLinear-by-linear test.
jjInitial predictors used to develop the A2 score.
{Initial predictors used to develop the GA2LEN score.
TABLE II. Association of the variables included in the final multivariable scores with the presence of asthma as assessed by the physician
Predictors
A2 score GA2LEN score
aOR 95% CI aOR 95% CI
1. Have you ever had asthma? * * 13.36 6.79-26.27
2. Did a physician confirm you had asthma? 7.91 3.17-19.77 † †
3. Do you still have asthma (previously diagnosed by a physician)? 4.28 1.33-13.79 † †
4. Have you had any asthma attack in the last 12 mo? 0.51 0.15-1.78 1.07 0.36-3.18
5. Are you currently taking any medicines including inhalers, aerosols, or tablets for
asthma?
4.07 1.23-13.47 6.02 2.01-18.00
6. Have you ever had wheezing or whistling in the chest at any time in the last 12 mo? 3.23 1.25-8.36 3.35 1.32-8.47
7. Have you had wheezing or whistling when you did not have a cold? 1.35 0.55-3.30 1.36 0.58-3.22
8. Have you been at all breathless when the wheezing noise was present? 1.13 0.42-3.00 1.37 0.55-3.42
9. Have you had an attack of shortness of breath after exercise in the last 12 mo? * * † †
10. Have you had an attack of shortness of breath that came on during the day when you
were at rest at any time in the last 12 mo?
2.05 0.85-4.98 † †
Constant 0.05 0.05
aOR, Adjusted odds ratio.
*Question tested but not included in the final score.
†Question not included in GA2LEN questionnaire.definitions requiring more positive answers have higher speci-
ficity and PPV but lower sensitivity, indicating that the proba-
bility of having asthma increases with an increasing score.
On the basis of a PPV of 85% or more in both cohorts, we
considered asthma to be present in patients with a sum of 4 or
more positive answers (Table III). Using this cutoff in the
derivation cohort, the A2 score and the GA2LEN score had high
accuracy (87.9% and 85.9%), high specificity (96.7% and
97.7%), and a sensitivity of 59.4% and 48.1%, respectively (see
Table E3 in this article’s Online Repository). In the validation
cohort, for the same cutoff based on PPV, the A2 score had a
slightly higher accuracy compared with the GA2LEN score
(89.4% vs 87.4%; Figure 3, C) and a higher sensitivity (48.3%
vs 37.9%; Figure 3, A), but the same specificity (99.2%;
Figure 3, A) (see Table E3 in this article’s Online Repository)
and false-positive rate (1%; Figure 3, E).
The cutoff to rule out asthma was based on an NPV of 95%
or more in both cohorts, which corresponds to a sum of less than
2 positive answers for the A2 score and 0 for the GA2LEN scoreAUC using 
direct sum,
AUC using 
weighted score,
Number of 
items
Cronbach 
α
% (95% CI) % (95% CI) (95% CI)
A2 score
90.4 91.3
8
0.887
(87.0-93.9) (87.9-94.7) (0.872-0.900)
GA2LEN score
89.0 90.5
6
0.852
(85.4-92.5) (87.0-94.0) (0.832-0.870)
A
FIGURE 2. (A) Discriminative properties and internal consistency. (B)
cohort (n ¼ 560).(Table III). Using this cutoff in the derivation cohort, the A2
score had a higher accuracy compared with the GA2LEN score
(84.3% vs 78.2%) and a higher specificity (83.8% vs 74.5%;
Figure 3, A), but both scores had high sensitivity (85.7% and
90.2%, respectively; Figure 3, A) (see Table E3 in this article’s
Online Repository). For this cutoff in the validation cohort, the
A2 score had a higher accuracy compared with the GA2LEN
score (89.4% vs 82.8%; Figure 3, B), but both scores had the
same sensitivity (93.1%; Figure 3, A) (see Table E3 in this ar-
ticle’s Online Repository); the scores also had similar NPVs
(98.2% vs 98.0%, respectively, for the A2 score and the
GA2LEN score; Table III) and the same false-negative rate (7%;
Figure 3, D).DISCUSSION
We developed and validated 2 multivariable scores, on the
basis of self-administered questions, for the identification of
asthma cases in epidemiological studies. The scores obtainedB
ROC curve of the scores, using participants from the derivation
TABLE III. Predictive values in derivation and validation cohorts
Score (no. of positive answers)
Derivation cohort (n [ 560) Validation cohort (n [ 151)
n (%) PPV % (95% CI) NPV % (95% CI) n (%) PPV % (95% CI) NPV % (95% CI)
A2 score
Possible Asthma
2* 183 (32.7) 62.3 (56.8-67.5) 95.0 (92.5-96.6) 41 (27.2) 65.9 (53.8-76.1) 98.2 (93.4-99.5)
3 130 (23.2) 77.7 (70.8-83.4) 92.6 (90.2-94.4) 24 (15.9) 79.2 (60.8-90.3) 92.1 (87.6-95.1)
Probable Asthma
4† 93 (16.6) 85.0 (76.8-90.6) 88.4 (86.2-90.4) 15 (9.9) 93.3 (65.7-99.0) 89.0 (85.0-92.0)
5 70 (12.5) 88.6 (79.2-94.0) 85.5 (83.4-87.4) 12 (7.9) 91.7 (59.7-98.8) 87.1 (83.5-89.4)
6 58 (10.4) 91.4 (81.2-96.3) 84.1 (82.1-85.8) 10 (6.6) 90.0 (54.3-98.6) 85.8 (82.6-88.5)
7 39 (7.0) 89.7 (76.0-96.0) 81.2 (79.6-82.7) 7 (4.6) 85.7 (42.9-98.0) 84.0 (81.4-86.4)
8 20 (3.6) 85.0 (62.8-95.0) 78.5 (77.4-79.6) 2 (1.3) 100.0 81.9 (80.4-83.3)
GA2LEN score
Possible Asthma
1* 229 (40.9) 52.4 (48.1-56.7) 96.1 (93.6-97.6) 51 (33.8) 52.9 (43.7-62.0) 98.0 (92.8-99.5)
2 167 (29.8) 62.9 (57.0-68.4) 92.9 (90.4-94.8) 31 (20.5) 71.0 (55.8-82.6) 94.2 (89.4-96.9)
3 111 (19.8) 78.4 (70.7-84.5) 89.8 (87.4-91.7) 21 (13.9) 81.0 (60.7-92.1) 90.8 (86.4-93.8)
Probable Asthma
4† 74 (13.2) 86.5 (77.2-92.4) 85.8 (83.7-87.7) 12 (7.9) 91.7 (59.7-98.8) 85.8 (83.7-87.7)
5 50 (8.9) 88.0 (76.2-94.4) 82.6 (80.8-84.2) 10 (6.6) 90.0 (54.3-98.6) 85.8 (82.6-88.5)
6 24 (4.3) 83.3 (63.5-93.5) 78.9 (77.7-80.1) 3 (2-0) 66.7 (15.8-95.5) 81.8 (80.2-83.2)
A2 score, Adult Asthma Epidemiological Score; GA2LEN score, Global Allergy and Asthma Network of Excellence Asthma Epidemiological Score; PPV, Positive predictive
value; NPV, negative predictive value.
*Cutoff of 2 (for the A2 score) and of 1 (for the GA2LEN score) for considering possible asthma (NPV of 95% or more, simultaneously in derivation and validation
cohorts).
†Cutoff of 4 for considering probable asthma (PPV 85% or more, simultaneously in derivation and validation cohorts).have very good properties to rule in/rule out asthma, providing,
for the first time, validated screening tools to be used in adult
asthma epidemiological studies and clinical screening/triage
settings.A B
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prevalence studies, a questionnaire with high specificity (few false
positives) and PPV for asthma diagnosis is preferable. Both our
scores had high specificity for asthma diagnosis, which is related
to the choice of a PPV-based cutoff to rule in asthma. However,
if our interest is to screen subjects to undergo a confirmatory
clinical evaluation, a questionnaire with high sensitivity (few false
negatives) and NPV is preferable in the first stage. In this case,
we can also use these scores to rule out asthma with the NPV-
based cutoff. A meta-analysis on screening tests for COPD
diagnostic accuracy determined a pooled sensitivity of 64.5%
(95% CI, 59.9%-68.8%) and a specificity of 65.2% (52.9%-
75.8%) for the COPD Diagnostic Questionnaire12; more
recently, the development and validation study of the Salzburg
COPD screening questionnaire reported a sensitivity of 69.1%
(56.6%-79.5%) and an NPV of 91.8% (87.5%-95.7%).11 The
values of sensitivity and NPV obtained for our scores, consid-
ering the cutoff to rule out asthma, were superior to those for the
screening tests for COPD. These findings indicate that the A2
score and the GA2LEN score may be used for asthma screening,
for instance, in clinical screening/triage settings to identify the
patients who could benefit from complete diagnostic workup.
They may help physicians in primary care or other specialties to
screen patients with asthma using a simple score with a high level
of discrimination and to identify the best candidates to be
referred for a diagnostic workup.
Pekkanen et al6 developed the ECRHS asthma score using the
question “Have you ever had asthma?” and with bronchial hy-
perreactivity as the comparator. It includes 8 questions (see the
“ECRHS score” section and Table E1 in this article’s Online Re-
pository). Applying the ECRHS asthma score to our data and
comparing it with the scores developed in the present study, we
found that the A2 score has the same number of questions as the
ECRHS asthma score, but shows better discriminative properties,
better internal consistency, and better diagnostic accuracy mea-
sures. However, the GA2LEN score has the advantage of being
shorter than the ECRHS asthma score, with comparable diagnostic
accuracy measures and better discriminative properties and inter-
nal consistency (see the “ECRHS score” section and Table E4 in
this article’s Online Repository at www.jaci-inpractice.org).
The A2 score includes questions on previous physician diag-
nosis (“Did a physician confirm you had asthma?” and “Do you
still have asthma (previously diagnosed by a physician)?”),
whereas the GA2LEN score asks “Have you ever had asthma?”
which can be preferable in settings with significant under-
diagnoses or difficult access to health care. Moreover, the A2
score has 1 additional question: “Have you had an attack of
shortness of breath that came on during the day when you were
at rest at any time in the last 12 months?” The GA2LEN score
may be considered to be more practical than the A2 score,
because it is shorter and 1 positive answer is enough to consider
possible asthma. The questions included in the A2 score that are
not in the GA2LEN score are part of the ECRHS10 and the
National Health and Nutrition Examination Survey.17
This study has its strengths and limitations. In the present
study, the Global Initiative for Asthma guidelines1 for asthma
diagnosis were followed by trained physicians, supported by
objective measurements, and blinded to the results of previous
self-administered questionnaires. A limitation of this study is
that we did not validate the scores in other populations and
settings, limiting its generalization. New studies using these
scores are being designed, and their application to other data setsis warranted for external validation. To improve the robustness
of the validation results, we used bootstrap resampling tech-
niques, obtaining very similar results to those reported for the
validation cohort (data not shown). Another limitation is the use
of PPV-/NPV-based cutoffs, which are measurements highly
dependable on asthma prevalence, and therefore these cutoff
values may not be transferable to other settings. As so, pre-
senting the results as continuous, before its dichotomization, is
advisable when applying the scores. Despite these limitations,
this study proposes scores developed on the basis of real-life data
from the general population and on asthma diagnosis by a
specialist that can be used for either asthma identification or
asthma screening/triage.CONCLUSIONS
Two scores based on self-administered questions were
developed and validated compared with physician-led asthma
diagnostic workup. These scores are short, easy to use, and can
be applied to identify the likely presence of asthma (prevalence)
or absence (screening) of asthma in epidemiological studies and
clinical screening/triage settings. The A2 score may be preferred
in studies aiming at maximum accuracy; however, the
GA2LEN score is shorter and would be preferable for com-
munities in which there may be difficulties related to physician
diagnosis of asthma. Asthma presence can be considered for
results of 4 or more in either the A2 score or the GA2LEN
score and can be excluded for results of 0 in the GA2LEN score
or of 0 to 1 in the A2 score. For results in between, asthma is
possible but requires a confirmatory clinical evaluation.
Nevertheless, the presentation of the results as a continuum
score before dichotomization using a cutoff is advisable. The
use of the A2 score and the GA2LEN score may contribute to
reducing the inconsistencies of asthma definitions across studies
and surveys and have the potential to be used in clinical set-
tings for screening/triage of asthma, where they may contribute
toward identifying the best candidates to be referred for diag-
nostic workup.
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ONLINE REPOSITORY
METHODS
This section describes in detail the methods of the ICAR
study.
The ICAR was a nationwide population-based observational
cross-sectional study. The study was conducted in accordance
with the ethical principles of the Declaration of Helsinki,
consistent with good clinical practice and the applicable regula-
tory requirements, and was approved by a hospital ethics com-
mittee (Comissão de Ética do Hospital São João EPE, on October
17, 2011) and by the national data protection committee (no.
12372/2011). The study protocol containing standard opera-
tional procedures was registered in ClinicalTrials.gov
(NCT01771120). All participants signed the consent form.
Sample size
The ICAR sample size calculations were based on the com-
parison of quality of life measured by the World Health Orga-
nization’s Quality of Life (WHOQOL-BREF)E1 questionnaire.
Considering previous participation and expressed willingness, we
estimate a nonparticipation rate of 33%. We have assumed a
WHOQOL-BREF SD of 3.0 units, on the basis of the previous
reports for different domains and populations.E1,E2 Conse-
quently, to identify a change of 1 unit in the WHOQOL-BREF
quality-of-life scores, in a 2-sided test, for a type I error proba-
bility of 0.05 and a statistical power of 80, 142 individuals in
each group are required. We include individuals without respi-
ratory symptoms at a 2:1 ratio to other groups. As so, we
calculated a sample of 750 individuals divided into 4 patient
groups: (1) patients with a self-reported diagnosis of asthma
alone (n ¼ 150), (2) patients with a self-reported diagnosis of
rhinitis alone (n ¼ 150), (3) patients with a self-reported diag-
nosis of asthma and rhinitis (n ¼ 150), and (4) patients with no
history of respiratory symptoms or diseases (n ¼ 300).
Participants and data collection
In the ICAR study, all subjects who have been included in the
INAsma (Inquérito Nacional sobre Asma) studyE3,E4 and who
have expressed their willingness to participate in a clinical
assessment were eligible along with their family members.
Furthermore, local media and posters were used to disseminate
the study and invite participants. Persons who did not under-
stand spoken Portuguese and who had cognitive or physical
conditions that could hamper their participation in the study
were excluded.
Data were collected between October 30, 2012, and July 12,
2014, in 2 allergy clinics (Lisbon and Porto) or by using a mobile
diagnostic unit, on the basis of the participants’ geographical
proximity.
Participants were screened by telephonic interview into 1 of
the 4 groups. A total of 858 participants, either with asthma and/
or rhinitis or with no previous history of respiratory symptoms or
diseases (aged between 3 and 89 years), were included from 90
Portuguese cities.
Data collection comprised anthropometric measurements, lung
function and exhaled nitric oxide tests, skin prick tests, a structured
clinical assessment, and standardized questionnaires. Anthropo-
metric measurements of height, weight, and waist/hip circumfer-
ence followed the procedures manual of the National Health and
Nutrition Examination Survey.E5 Lung function tests included
spirometry with postbronchodilator reversibility (EasyOne Pro,ndd, Zurich, Switzerland, and Jaeger IOS, CareFusion, SanDiego,
Calif), carbon monoxide in exhaled air (SmokeCheck, Micro
Medical, Kent, UK), and exhaled nitric oxide (NIOX Mino,
Aerocrine AB, Solna, Sweden), and were done according to stan-
dardized methods.E6-E8 Atopy was determined with skin prick
tests. Blood sampling allowed for the determination of total IgE,
eosinophilic cationic protein, and C-reactive protein. The struc-
tured clinical assessment performed by a trained physician
included physical examination, comorbidities screening (eg,
gastroesophageal reflux and anxiety/depression), use of health re-
sources and medications because of asthma/rhinitis, assessment of
the degree of control of the allergic diseases, family history, envi-
ronmental exposures (at home and workplace), and social habits.
In the ICAR study, self-administered questionnaires included the
assessment of the following:
1. disease symptoms and control, using the Portuguese versions
of the GA2LEN survey questionnaire,E9 the allergy airway
diseases screening (ASF) questionnaire,E10 visual analog scales,
the Control of Allergic Rhinitis and Asthma Test,E11 the
Control of Allergic Rhinitis and Asthma Test for kids,E12 and
the Allergic Rhinitis Control TestE13;
2. quality of life, using the Portuguese versions of the EuroQol
5-dimensional questionnaire,E14 the WHOQOL-BREF,E1
the Mini Asthma Quality of Life Questionnaire,E15 the
Mini Rhinoconjunctivitis Quality of Life Questionnaire,E16
and the Paediatric Asthma Caregiver’s Quality of Life
QuestionnaireE17;
3. work/school absenteeism and impairment, using the Work
Productivity and Activity Impairment questionnaireE18;
4. adherence to prescribed treatment, using the Medication
Adherence Report ScaleE19; and
5. physical activity, using the International Physical Activity
Questionnaire.E20
EXPLORATORY FACTOR ANALYSIS
This section contains complementary material on exploratory
factor analysis results.
The A2 score derivation was obtained by exploratory factor
analysis as follows. The predictors “asthma diagnosis by a
physician” and “asthma self-report” were highly correlated and
had similar loading factors; however, because “asthma diagnosis
by a physician” improved the Cronbach a of the final score, it
was included, whereas “asthma self-report” was excluded.
“Waking up with chest tightness” and “dry cough during the
night not associated with infection” were excluded because they
had a low item-total correlation. The best Cronbach a was ob-
tained when “waking up with an attack of cough,” “waking up
with an attack of shortness of breath,” and “having an attack of
shortness of breath after exercise” were excluded. The final A2
score included 8 predictors in 2 factors with eigenvalues of 3.997
(predictors 2-5 and 10; Table II) and 3.535 (predictors 6-8).
For the GA2LEN score, “phlegm when coughing” was
excluded because it had more than 95% responses in a single
category; “waking up with chest tightness” and “hospitalization
because of asthma” were excluded because they had a low item-
total correlation. The best Cronbach a was obtained when
“waking up with an attack of cough” and “waking up with an
attack of shortness of breath” were excluded. The final GA2LEN
score included 6 predictors in 2 factors with eigenvalues of 2.954
(predictors 6-8; Table II) and 2.860 (predictors 1, 4, and 5).
TABLE E1. Initial predictors (Portuguese and English versions) used to develop the multivariable prediction models and predictors
included in the ECRHS asthma score previously developed
Portuguese version of the predictors Predictors
From literature,
as suggested
by Sá-Sousa
et al
(A2 score)
From
GA2LEN
questionnaire
(GA2LEN score)
Asthma score
based
on ECRHS
1. Já alguma vez teve asma? 1. Have you ever had asthma?   
2. Alguma vez um médico lhe disse
que tem asma?
2. Did a physician confirm you had asthma? 
3. Ainda tem asma? 3. Do you still have asthma? 
4. Alguma vez esteve hospitalizado
por asma?
4. Have you ever been hospitalized because
of asthma?

5. Teve um ataque de asma nos
últimos 12 meses?
5. Have you had any asthma attack in the last
12 mo?
  
6. Presentemente está a tomar
remédios (inaladores, aerossóis ou
comprimidos) para a asma?
6. Are you currently taking any medicines
including inhalers, aerosols, or tablets for
asthma?
  
7. Alguma vez teve chiadeira ou
pieira no peito nos últimos 12
meses?
7. Have you ever had wheezing or whistling
in the chest at any time in the last 12 mo?
 
8. Teve a chiadeira ou a pieira sem
estar constipado?
8. Have you had this wheezing or whistling
when you did not have a cold?
 
9. Teve falta de ar quando a
chiadeira estava presente?
9. Have you been at all breathless when the
wheezing noise was present?
  
10. Alguma vez foi acordado devido a
um ataque de falta de ar, depois de
atividade física moderada ou
intensa, nos últimos 12 meses?
10. Have you had an attack of shortness of
breath after exercise in the last 12 mo?
 
11. Alguma vez teve uma crise de
falta de ar, que surgiu durante o
dia, quando estava em repouso,
nos últimos 12 meses?
11. Have you had an attack of shortness of
breath that came on during the day when
you were at rest at any time in the last 12
mo?
 
12. Acordou com a sensação de
aperto no peito nos últimos 12
meses?
12. Have you woken up with the feeling of
tightness in your chest at any time in the
last 12 mo?
  
13. Alguma vez foi acordado devido a
um ataque de falta de ar nos
últimos 12 meses?
13. Have you been woken up by an attack of
shortness of breath at any time in the last
12 mo?
  
14. Alguma vez foi acordado devido a
um ataque de tosse nos últimos 12
meses?
14. Have you been woken up by an attack of
coughing at any time in the last 12 mo?
 
15. Alguma vez teve tosse seca
durante a noite nos últimos 12
meses, não contando com a tosse
associada a constipação ou
infeção?
15. In the last 12 mo, have you had a dry
cough during the night, apart from a cough
associated with a cold or a chest infection?

16. Na maioria dos dias produz muco
do seu peito durante um período
de três meses por ano?
16. Did you have phlegm when coughing for
at least 3 mo in the last year?

TABLE E2. Diagnostic accuracy measures for each predictor in the derivation and validation cohorts
Predictor
Derivation cohort (n [ 560) Validation cohort (n [ 151)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
1. Have you ever had asthma? 76.7 (69.0-83.8) 91.6 (88.7-94.0) 73.9 (66.2-80.8) 92.7 (89.9-94.9) 69.0 (51.0-91.8) 91.8 (86.1-95.8) 66.7 (48.9-81.7) 92.6 (87.0-96.4)
2. Did a physician confirm you had asthma? 76.7 (69.0-83.8) 93.0 (90.3-95.1) 77.3 (69.6-83.9) 92.8 (90.0-95.0) 65.5 (47.4-91.8) 91.8 (86.1-95.8) 65.5 (47.4-81.0) 91.8 (86.1-95.8)
3. Do you still have asthma (previously
diagnosed by a physician)?
67.7 (59.4-75.2) 96.7 (94.7-98.1) 86.5 (79.1-92.2) 90.6 (87.7-93.0) 62.1 (43.9-78.2) 95.1 (90.3-98.0) 75.0 (55.7-89.2) 91.3 (85.6-95.4)
4. Have you ever been hospitalized because
of asthma?
22.6 (16.0-30.1) 97.7 (95.9-98.8) 75.0 (60.3-86.6) 76.3 (72.6-79.6) 20.7 (8.8-37.5) 98.4 (95.0-99.7) 75.0 (40.9-95.3) 80.8 (74.0-86.5)
5. Have you had any asthma attack in the last
12 mo?
33.1 (25.5-41.3) 98.4 (96.9-99.3) 86.3 (75.1-93.9) 82.5 (79.1-85.6) 20.7 (8.8-37.5) 99.2 (96.4-100.0) 85.7 (50.6-99.1) 84.0 (77.5-89.4)
6. Are you currently taking any medicines
including inhalers, aerosols, or tablets for
asthma?
45.9 (37.5-54.4) 98.8 (97.5-99.6) 92.4 (84.4-97.2) 85.4 (82.1-88.4) 34.5 (19.0-52.6) 99.2 (96.4-100.0) 90.9 (65.7-99.5) 86.4 (80.1-91.4)
7. Have you ever had wheezing or whistling
in the chest at any time in the last 12 mo?
69.9 (61.8-77.3) 80.1 (76.1-83.7) 52.2 (44.9-59.5) 89.5 (86.2-92.3) 72.4 (54.7-86.3) 86.1 (79.2-91.4) 55.3 (39.5-70.3) 92.9 (87.2-96.7)
8. Have you had wheezing or whistling when
you did not have a cold?
47.4 (39.0-55.8) 90.4 (87.4-93.0) 60.6 (51.0-69.6) 84.6 (81.2-87.8) 48.3 (30.8-66.0) 96.7 (92.5-99.0) 77.8 (55.7-92.5) 88.7 (82.6-93.3)
9. Have you been at all breathless when the
wheezing noise was present?
57.9 (49.4-66.1) 90.4 (87.4-93.0) 65.3 (56.4-73.5) 87.3 (84.0-90.2) 58.6 (40.5-75.2) 94.3 (89.2-97.5) 70.8 (51.2-86.3) 90.6 (84.7-94.8)
10. Have you had an attack of shortness of
breath after exercise in the last 12 mo?
21.8 (15.4-29.3) 96.3 (94.2-97.8) 64.4 (49.9-77.3) 79.8 (76.2-83.1) 27.6 (13.7-45.3) 99.2 (96.4-100.0) 88.9 (59.5-99.3) 85.2 (78.8-90.4)
11. Have you had an attack of shortness of
breath that came on during the day when
you were at rest at any time in the last 12
mo?
39.1 (31.1-47.5) 93.9 (91.4-95.9) 66.7 (55.8-76.5) 83.2 (79.9-86.4) 37.9 (21.8-56.1) 98.4 (95.0-99.7) 84.6 (59.6-97.3) 87.0 (80.7-91.1)
12. Have you woken up with the feeling of
tightness in your chest at any time in the
last 12 mo?
29.3 (22.0-37.4) 86.2 (82.7-89.2) 39.8 (30.5-49.7) 79.7 (75.8-83.2) 34.5 (19.0-52.6) 87.7 (81.1-92.7) 40.0 (22.5-59.5) 84.9 (78.0-90.4)
13. Have you been woken up by an attack of
shortness of breath at any time in the last
12 mo?
25.6 (18.7-33.4) 94.6 (92.2-96.5) 59.6 (46.7-71.8) 80.3 (76.7-83.6) 20.7 (8.8-37.5) 93.4 (88.1-96.9) 42.9 (19.8-68.3) 83.2 (76.4-88.8)
14. Have you been woken up by an attack of
coughing at any time in the last 12 mo?
52.6 (44.2-61.0) 63.5 (58.8-67.9) 31.0 (25.2-37.2) 81.1 (76.7-85.1) 58.6 (40.5-75.2) 69.7 (61.2-77.4) 31.5 (20.2-44.5) 87.6 (80.1-93.2)
15. In the last 12 mo, have you had a dry
cough during the night, apart from a cough
associated with a cold or a chest infection?
58.6 (50.2-66.8) 66.3 (61.7-70.7) 35.1 (29.1-41.6) 83.7 (79.5-87.4) 65.5 (47.4-81.0) 67.2 (58.6-75.1) 32.2 (21.2-44.7) 89.1 (81.7-94.4)
16. Did you have phlegm when coughing for
at least 3 mo in the last year?
8.3 (4.4-13.7) 98.1 (96.5-99.1) 57.9 (35.8-78.0) 76.3 (72.6-79.6) 6.9 (1.2-19.8) 98.4 (95.0-99.7) 50.0 (10.7-89.3) 80.8 (74.0-86.5)
TABLE E3. Diagnostic accuracy measures in derivation and validation cohorts
Score (no. of
positive answers)
Derivation cohort (n [ 560) Validation cohort (n [ 151)
n (%)
Sensitivity Specificity PPV NPV Accuracy
n (%)
Sensitivity Specificity PPV NPV Accuracy
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % % (95% CI) % (95% CI) % (95% CI) % (95% CI) %
A2 score
Possible Asthma
2* 183 (32.7) 85.7 (78.6-91.2) 83.8 (80.0-87.2) 62.3 (56.8-67.5) 95.0 (92.5-96.6) 84.3 41 (27.2) 93.1 (77.2-99.2) 88.5 (81.5-93.6) 65.9 (53.8-76.1) 98.2 (93.4-99.5) 89.4
3 130 (23.2) 75.9 (67.8-82.9) 93.2 (90.4-95.4) 77.7 (70.8-83.4) 92.6 (90.2-94.4) 89.1 24 (15.9) 65.5 (45.7-82.1) 95.9 (90.7-98.7) 79.2 (60.8-90.3) 92.1 (87.6-95.1) 90.0
Probable Asthma
4† 93 (16.6) 59.4 (50.5-67.8) 96.7 (94.6-98.2) 85.0 (76.8-90.6) 88.4 (86.2-90.4) 87.9 15 (9.9) 48.3 (29.5-67.5) 99.2 (95.5-100.0) 93.3 (65.7-99.0) 89.0 (85.0-92.0) 89.4
5 70 (12.5) 46.6 (37.9-55.5) 98.1 (96.3-99.2) 88.6 (79.2-94.0) 85.5 (83.4-87.4) 85.9 12 (7.9) 37.9 (20.7-57.7) 99.2 (95.5-100.0) 91.7 (59.7-98.8) 87.1 (83.5-89.4) 87.4
6 58 (10.4) 39.9 (31.5-48.7) 98.8 (97.3-99.6) 91.4 (81.2-96.3) 84.1 (82.1-85.8) 84.8 10 (6.6) 31.0 (15.3-50.8) 99.2 (95.5-100.0) 90.0 (54.3-98.6) 85.8 (82.6-88.5) 86.1
7 39 (7.0) 26.3 (19.1-34.7) 99.1 (97.6-99.7) 89.7 (76.0-96.0) 81.2 (79.6-82.7) 81.8 7 (4.6) 20.7 (7.99-39.7) 99.2 (95.5-100.0) 85.7 (42.9-98.0) 84.0 (81.4-86.4) 84.1
8 20 (3.6) 12.8 (7.6-19.7) 99.3 (98.0-99.9) 85.0 (62.8-95.0) 78.5 (77.4-79.6) 78.8 2 (1.3) 6.9 (0.9-22.8) 100.0 (97.0-100.0) 100.0 81.9 (80.4-83.3) 82.1
GA2LEN score
Possible Asthma
1* 229 (40.9) 90.2 (83.8-94.7) 74.5 (70.1-78.5) 52.4 (48.1-56.7) 96.1 (93.6-97.6) 78.2 51 (33.8) 93.1 (77.2-99.1) 80.3 (72.2-87.0) 52.9 (43.7-62.0) 98.0 (92.8-99.5) 82.8
2 167 (29.8) 79.0 (71.0-85.5) 85.5 (81.8-88.7) 62.9 (57.0-68.4) 92.9 (90.4-94.8) 83.9 31 (20.5) 75.9 (56.5-89.7) 92.6 (86.5-96.6) 71.0 (55.8-82.6) 94.2 (89.4-96.9) 89.4
3 111 (19.8) 65.4 (56.7-73.4) 94.4 (91.8-96.4) 78.4 (70.7-84.5) 89.8 (87.4-91.7) 87.5 21 (13.9) 58.6 (38.9-76.5) 96.7 (91.8-99.1) 81.0 (60.7-92.1) 90.8 (86.4-93.8) 89.4
Probable Asthma
4† 74 (13.2) 48.1 (39.4-57.0) 97.7 (95.7-98.9) 86.5 (77.2-92.4) 85.8 (83.7-87.7) 85.9 12 (7.9) 37.9 (20.7-57.7) 99.2 (95.5-100.0) 91.7 (59.7-98.8) 85.8 83.7-87.7 87.4
5 50 (8.9) 33.1 (25.2-41.8) 98.6 (97.0-99.5) 88.0 (76.2-94.4) 82.6 (80.8-84.2) 83.0 10 (6.6) 31.0 (15.3-50.8) 99.2 (95.5-100.0) 90.0 (54.3-98.6) 85.8 (82.6-88.5) 86.1
6 24 (4.3) 15.0 (9.4-22.3) 99.1 (97.6-99.7) 83.3 (63.5-93.5) 78.9 (77.7-80.1) 79.1 3 (2-0) 6.9 (0.9-22.8) 99.2 (95.5-100.0) 66.7 (15.8-95.5) 81.8 (80.2-83.2) 81.5
A2 score, Adult Asthma Epidemiological Score; GA2LEN score, Global Allergy and Asthma Network of Excellence Asthma Epidemiological Score; PPV, Positive predictive value; NPV, negative predictive value.
*Cutoff of 2 (for the A2 score) and of 1 (for the GA2LEN score) for considering possible asthma (NPV of 95% or more, simultaneously in derivation and validation cohorts).
†Cutoff of 4 for considering probable asthma (PPV 85% or more, simultaneously in derivation and validation cohorts.
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.THE ECRHS SCORE
This section contains details on the previously developed
ECRHS asthma score and the application of this score to our
data. The previously developed ECRHS asthma scoreE21 has 8
questions:
1. Have you been at all breathless when the wheezing noise was
present?
2. Have you woken up with the feeling of tightness in your chest
at any time in the last 12 months?
3. Have you had an attack of shortness of breath that came on
during the day when you were at rest at any time in the last 12
months?
4. Have you had an attack of shortness of breath after exercise in
the last 12 months?
5. Have you been woken up by an attack of shortness of breath
at any time in the last 12 months?
6. Have you ever had asthma?
7. Have you had any asthma attack in the last 12 months?
8. Are you currently taking any medicines including inhalers,
aerosols, or tablets for asthma?
We applied the ECRHS asthma score to our data, and its
performance was tested in the derivation and validation cohorts.
The AUC obtained by applying the previously developed
ECRHS asthma score to our data was 86.8% (95% CI, 82.8%-
90.8%) and the Cronbach a was 0.826 (95% CI, 0.804-0.847).
The diagnostic accuracy measures are described in Table E4.
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